Abstract: This present disclosure provides compounds which are useful in treating medical disorders. More particularly, compounds are provided for targeted degradation of TAF1 which are useful in the treatment of cancers.

Abstract: Disclosed are a suspending agent for a negative electrode slurry of a lithium ion battery and a preparation method and application thereof. The suspending agent for the negative electrode slurry comprises the following ingredients in parts by weight: 87 parts to 94 parts of main suspending agent, 0.1 part to 1 part of solubilizing agent, 5 parts to 8 parts of synergist, and 0.1 part to 1 part of pH value regulator. According to the invention, by adding the suspending agent into the negative electrode slurry of the lithium ion battery, a traditional negative electrode suspending agent sodium carboxymethyl cellulose (hereinafter referred to as CMC) material can be replaced, the suspending agent has better suspension stability compared with the CMC material, an amount of the suspending agent is reduced compared with the CMC material.

Abstract: Disclosed herein is a method for treating a tumor having a temperature sensitive p53 (ts p53) mutation in a subject in need thereof. The method involves first administering to the subject a therapeutically effective amount of a chemotherapeutic drug, then inducing moderate hypothermia in the tumor for a duration sufficient to activate the mutant p53 to enhance the efficacy of the drug.

Abstract: Disclosed are inhibitors for TAF1. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: A cathode slurry of a lithium ion battery, comprising the following ingredients in parts by weight: 50 to 80 parts of solvent, 5 to 9 parts of secondary assistant, 10 to 40 parts of main dispersing agent, and 0.1 to 3 parts of pH value regulator; a dispersing agent is added into the cathode slurry of the lithium ion battery, so that a dispersity of a solid material in the cathode slurry is improved, and a viscosity of the slurry is reduced due to a good dispersity; when coating is carried out with the same viscosity, the cathode slurry added with the dispersing agent is used as a high-solid-content slurry, and multiple experiments show that, when a dispersing agent effective matter accounting for 0.3% of a total solid amount is added, a solid content is increased by 2% to 3% under the same viscosity.

Abstract: The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent. The invention further provides in vitro and in vivo models to evaluate the therapeutic effectiveness of a recently identified anti-human-MDM2 antisense oligonucleotide in the treatment of human colorectal cancers.

Abstract: The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent. The invention further provides in vitro and in vivo models to evaluate the therapeutic effectiveness of a recently identified anti-human-MDM2 antisense oligonucleotide in the treatment of human colorectal cancers.

Abstract: The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent.